INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...
Stiolto Respimat (tiotropium bromide and olodaterol) is a brand-name inhalation spray prescribed for chronic obstructive pulmonary disease (COPD) in adults. Stiolto Respimat can cause side effects, ...
FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...
RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results